| Autor: |
Mello FK; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Sampaio TB; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Neuberger B; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Mallmann MP; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Fighera MR; Department of Neuropsychiatry, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Royes LFF; Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Furian AF; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil., Larrick JW; Panorama Research Institute, 1230 Bordeaux Dr., Sunnyvale, California 94089, United States., Oliveira MS; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil. |
| Abstrakt: |
Status epilepticus (SE) is a medical emergency associated with high mortality and morbidity. Na + , K + -ATPase, is a promising therapeutic target for SE, given its critical role in regulation of neuron excitability and cellular homeostasis. We investigated the effects of a Na + , K + -ATPase-activating antibody (DRRSAb) on short-term electrophysiological and behavioral consequences of pilocarpine-induced SE. Rats were submitted to pilocarpine-induced SE, followed by intranasal administration (2 μg/nostril). The antibody increased EEG activity following SE, namely, EEG power in theta, beta, and gamma frequency bands, assessed by quantitative analysis of EEG power spectra. One week later, DRRSAb-treated animals displayed less behavioral hyperreactivity in pick-up tests and better performance in novel object recognition tests, indicating that the intranasal administration of this Na + , K + -ATPase activator immediately after SE improves behavioral outcomes at a later time point. These results suggest that Na + , K + -ATPase activation warrants further investigation as an adjunctive therapeutic strategy for SE. |
